A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors
This study is to evaluate the tolerability and safety of ONO-7428 in participants with unresectable advanced or recurrent solid tumors.
Solid Tumor|NSCLC
DRUG: ONO-7428
Dose-limiting toxicities（DLT）, 21 days|Adverse event (AE), Up to 2 years
Cmax, Up to 2 years|Tmax, Up to 2 years|Area under the Plasma Concentration versus Time Curve (AUC), Up to 2 years|Ctrough, Up to 2 years|Objective Response Rate (ORR), Up to 2 years|Disease Control Rate (DCR), Up to 2 years|Overall Survival (OS), Up to 2 years|Progression-Free Survival (PFS), Up to 2 years|Duration of Response (DOR), Up to 2 years|Time to Response (TTR), Up to 2 years|Best Overall Response (BOR), Up to 2 years|Percent change from baseline in the sum of diameters of target lesions, Up to 2 years|Best reduction percent change from baseline in the sum of diameters of target lesions, Up to 2 years
This study is to evaluate the tolerability and safety of ONO-7428 in participants with unresectable advanced or recurrent solid tumors.